Shots:Innovent & Roche have entered into a collaboration & exclusive license agreement for developing IBI3009 to treat advanced SCLC
As per the terms, Roche secures exclusive worldwide rights to develop, manufacture & commercialize IBI3009 plus will lead full development after early-stage studies, conducted jointly. Innovent will get $80M upfront, up to $1B development…
